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The progressive nature of bipolar disorder
Many psychiatric disorders, including bipolar dis-
order follow a progressive path, and manifest a vari-
able but observable trajectory. While Kraepelin (1921)
described a progressive dementing process in schizo-
phrenia, and conceptualized the illness as a stepwise,
progressive disorder, he saw bipolar disorder as
having a more episodic pattern. Nevertheless, it has
become clear that bipolar disorder too shares a
temporal progression in phenomenology, treatment
response, neurobiology and functional impairment.
The notion of clinical staging, long used in oncology
and medicine and more recently in psychiatry, postu-
lates that there is a stepwise progression through a
series of identiﬁable steps, which have characteristic
features and potential treatment implications (Berk
et al., 2007b ; McGorry et al., 2006). The earliest stage,
stage 0, applies to individuals who have known risk
factors for the disorder such as genetic vulnerability,
pregnancy and obstetric complications childhood psy-
chological, physical or sexual abuse, proximal psy-
chological stress, and substance abuse, but no overt
symptoms. The prodromal stage, stages 1a and 1b
comprise mild, non-speciﬁc and identiﬁable disorder-
speciﬁc symptoms respectively. Stage 2 is the ﬁrst
episode of illness, and since mania is mandatory for a
DSM-IV (APA, 2000) and ICD-10 (WHO, 2005) diag-
nosis of bipolar I, stage 2 is synonymous with the ﬁrst
episode of mania or hypomania. Stage 3 is that of
recurrence, and is subdivided into stage 3a, with the
recurrence of subthreshold symptoms; stage 3b with
threshold symptoms; and stage 3c with persistent
relapses. Stage 4 is the stage of treatment resistance,
manifest by a persistent unremitting course.
Recurrence may be self-seeding, with illness beget-
ting a further increased risk of recurrence. A reduction
in inter-episode duration with increasing number
of episodes, has been known since Kraepelin, and
has been extensively replicated (Kessing et al., 1998 ;
Kraepelin, 1921 ; Roy-Byrne et al., 1985 ; Zis et al.,
1980). Further support for the progressive nature of
the disorder comes from clinical, neuroimaging and
neurocognitive studies. The characteristic and lengthy
delay between the onset of bipolar disorder and the
introduction of mood-stabilizing medication (Berk
et al., 2007a), is associated with a potential reduction
in the likelihood of response to treatment. Lithium
(Franchini et al., 1999 ; Swann et al., 1999), and even
psychotherapy (Scott et al., 2006) may be less useful if
used later in the course of illness. Structural brain
changes are not consistently found at illness onset, and
appear to become more evident with chronicity (Lyoo
et al., 2006; Strakowski et al., 2002). Cognitive deﬁcits
are well described in the disorder, and again there
is again some evidence that this is related to number
of episodes (El-Badri et al., 2001 ; Robinson and
Ferrier, 2006), although the data is rather inconsistent.
One report suggested that individuals after a ﬁrst or
second episode showed minimal cognitive diﬀerences
compared to controls in terms of cognitive functioning
(Lopez et al., 2008), whereas those with chronic illness
showed signiﬁcant deﬁcits when compared to both
controls and early episode bipolar patients on all scales.
Recurrence is further associated with poorer social ad-
justment (Matza et al., 2005), more hospitalizations
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(Goldberg and Ernst, 2002), greater suicide risk
(Hawton et al., 2005), higher rates of comorbidity,
especially substance abuse (Brady and Goldberg, 1996),
forensic complications, and failure to meet age-speciﬁc
developmental tasks (Conus and McGorry, 2002).
Mechanisms underlying neuroprogression
There are a number of models for understanding this
change in the nature of the illness with course. Post
(1992), in his neurosensitization model, suggests that
multiple episodes lead to permanent alterations in
neuronal activity, which may be transduced at the
level of gene expression, and these in turn may form
the neurobiological basis of a greater relapse liability,
and potentially poorer response to medication. The
allostatic load hypothesis (Kapczinski et al., 2008),
models the cumulative ‘wear and tear’ of stressors,
illness itself, and aggravating factors such as substance
use, and suggests that these factors are transduced
through modulation of brain circuits. This is hypo-
thesized to result in the observed structural changes,
the associated cognitive decline and the reported
decreasing responsiveness to therapy. This process
further increases the vulnerability to future illness
episodes. In this model, mood stabilizers are hypo-
thesized to exert an eﬀect on neurons that opposes the
impact of chronic stress.
The biochemical mediators of this process are
incompletely understood, but are thought to include
stress sensitization via cortisone, inﬂammatory pro-
cesses, oxidative stress, mediation via GABA, thyro-
tropin-releasing hormone and Neuropeptide Y, and
changes to neurotrophins including BDNF (Berk
et al., 2008b ; Post, 2007 ; Wadee et al., 2002). Post
further hypothesized the failure of endogenous com-
pensatory mechanisms over time as a component of
the mechanism of neuroprogression.
The paper of Kauer-Sant’Anna et al. (2008) provides
mechanistic support for this hypothesis, and is the ﬁrst
published data that shows a stage-dependent change
in neurochemistry in bipolar disorder. This is of par-
ticular relevance, as more than perhaps any major
psychiatric disorder, bipolar disorder lacks a coherent
pathophysiological hypothesis. As a consequence, ra-
tional drug discovery has been markedly restricted,
with almost all agents in current use either discovered
serendipitously, or borrowed from other indications.
The presence of known targets opens the door to the
development of strategic interventions. The principal
ﬁnding of the paper was that BDNF was decreased
only in the late stage of the disorder ; this is concordant
with the prediction of Post (2007), who argued that
a failure of compensatory mechanisms occurs with
neuroprogression in the disorder. Given the role of
BDNF in neuronal survival and proliferation, this
provides support for role of neurotrophins in neuro-
progression. The paper also examined pro- and anti-
inﬂammatory cytokines, in particular TNF-a, IL-6 and
IL-10. The pro-inﬂammatory cytokines IL-6 and TNF-a
were elevated in both early- and late-stage disorder,
while the anti-inﬂammatory cytokine IL-10 was in-
creased early but not late in the disorder. TNF-a, while
elevated throughout the course, was higher later than
earlier in the disorder. This conﬁrms the presence of an
inﬂammatory state (Wadee et al., 2002), that is greater
later in the disorder, and could be due to progression
of the primary underlying process, or due again to
failure of homeostatic mechanisms consequent to
episode progression. There is a suggestion that some
elements of the inﬂammatory process may be state
dependent, as Kim et al. (2007) reported that IL-6
elevation in mania resolves with clinical remission,
while TNF-a did not change with clinical remission.
There is unpublished data on stage-dependent
changes in oxidative parameters. Glutathione is the
brain’s principal free radical scavenger, and dysregu-
lation of the glutathione system is implicated in bi-
polar disorder (Berk et al., 2008b; Ng et al., 2008).
Andreazza et al. (2007) have reported that the ac-
tivity of key enzymes in the glutathione pathway,
glutathione reductase, and glutathione S-transferase
are increased in late-stage patients compared to early-
stage patients and controls. They hypothesized that the
change in antioxidant enzymes in late-stage patients
may be an adaptive result of the cumulative eﬀect of
oxidative stress with progression of the disorder. This
again is concordant with the prediction of Post (2007).
Other mediators of neuroprogression have been
examined. In depression, the CSF metabolome diﬀers
between responders and non-responders to treatment,
although speciﬁc biomarkers have not yet been
identiﬁed. A tendency for individuals to switch from
unipolar to a bipolar phenomenology with time is well
described. It has been hypothesized that this conver-
sion from depression to a bipolar phenotype may be
due to epigenetic modiﬁcation as part of the disease
process, and may be associated with treatment resist-
ance. This may be a result of histone acetylation or
DNA methylation altering gene expression (Holsboer,
2008).
Neuroprotective eﬀects of mood stabilizers
Mood stabilizers impact the pathways and mechan-
isms that are associated with neuroprogression in
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bipolar disorder, via the prevention of the biochemical
mediators of the tissue damage, that manifests as
the observed staged structural, cognitive and clinical
changes. Both lithium and valproate increase levels
of the anti-apoptotic protein bcl-2 in animal studies
(Chen et al., 1999 ; Manji et al., 2000). Atypical anti-
psychotics also increase bcl-2 levels (Bai et al., 2004).
Glycogen synthase kinase-3 (GSK-3), a cytoprotective
protein that regulates apoptosis, cellular plasticity
and resilience is inhibited by lithium (Gould and
Manji, 2005 ; Klein and Melton, 1996). Lithium protects
against excitotoxic apoptosis, which contributes to hip-
pocampal atrophy, and increases N-acetylaspartate,
a marker of neuronal viability (Malhi et al., 2002 ;
Malhi and Yatham, 2007). Lithium treatment increases
grey matter in individuals with bipolar disorder
(Moore et al., 2000a,b).
Oxidative stress is increased in bipolar disorder.
There is evidence that lithium and valproate reduce
oxidative stress (Ng et al., 2008). Similarly, lithium,
valproate, and atypical antipsychotics such as quet-
iapine, increase BDNF (Bai et al., 2003 ; Martinowich
et al., 2007). These common properties of otherwise
biochemically diverse mood stabilizers provide tenta-
tive support for a shared mechanism of action, that
further correlates with the neuroprogressive changes
documented by Kauer-Sant’Anna et al. (2008).
The biochemical mechanisms of neuroprogression
appear to include illness stage-related alterations in
inﬂammatory cytokines, neurotrophins and oxidative
stress. These data further support the principle of
neuroprotection, and the possibility of secondary pre-
vention of the disorder as viable therapeutic targets.
The clinical implications of these ﬁndings suggest that
there may be an opportunity early in the course of
the disorder, whereby the progressive trajectory of the
disorder could be modiﬁed. This evidence further
supports the imperative to reduce the lengthy delay
to diagnosis and initiation of appropriate therapy.
A focus on early intervention at a service level
would support the development of specialized early
intervention services. Last, these biochemical ﬁndings
might additionally provide rational intervention tar-
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